The content is available as a PDF (358.2 KB).
letter . 2020 Oct 19:ciaa1600. doi: 10.1093/cid/ciaa1600
Favipiravir as an antiviral agent in COVID-19: same script, different cast?
Nicolas Dauby
1,2,3,✉
Nicolas Dauby
1
Department of Infectious Diseases, CHU Saint-Pierre,
Brussels
2
Institute for Medical Immunology, Université Libre de Bruxelles
(ULB)
3
Environmental Health Research Centre, Public Health School, Université Libre de
Bruxelles (ULB), Brussels, Belgium
Find articles by Nicolas Dauby
1
Department of Infectious Diseases, CHU Saint-Pierre,
Brussels
2
Institute for Medical Immunology, Université Libre de Bruxelles
(ULB)
3
Environmental Health Research Centre, Public Health School, Université Libre de
Bruxelles (ULB), Brussels, Belgium
✉
Corresponding author: Nicolas Dauby, M.D., Ph.D., Department of Infectious Diseases, CHU Saint-Pierre, Rue Haute, 322, 1000 Brussels, Nicolas.Dauby@stpierre-bru.be
Received 2020 Aug 11.
© The Author(s) 2020. Published by Oxford University Press for the
Infectious Diseases Society of America. All rights reserved. For permissions, e-mail:
journals.permissions@oup.com.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC7665399 PMID: 33075124
See the article "Avifavir in Treating Patients with Moderate Covid 19", ciaa1601.